Monita Muralidharan

Monita Muralidharan

Auto-generated profile, based on publicly available information

Monita Muralidharan

Quantitative Biosciences Institute, University of California, San Francisco

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2020 in Cell
Verified
Journal Article
Closed access
MBMehdi Bouhaddou
Mehdi Bouhaddou
DMDanish Memon
Danish Memon
BMBjoern Meyer
Bjoern Meyer
KWKris White
Kris White
VRVeronica V. Rezelj
Veronica V. Rezelj
NKNevan J. Krogan
Nevan J. Krogan

8 March 2011 in Bioconjugate Chemistry
Verified
Journal Article
Closed access
GMGopa Mitra
Gopa Mitra
MMMonita Muralidharan
Monita Muralidharan
JPJennifer Pinto
Jennifer Pinto
KSKrishnamachari Srinivasan
Krishnamachari Srinivasan
AMAmit Kumar Mandal
Amit Kumar Mandal

9 October 2019 in The FEBS Journal
Verified
Journal Article
Open access
PDF file
MMMonita Muralidharan
Monita Muralidharan
VBVijay Bhat
Vijay Bhat
AMAmit Kumar Kumar Mandal
Amit Kumar Kumar Mandal
Glycated hemoglobin (GHb) is the indicator of the long‐term glycemic index of an individual. GHb is formed by the irreversible modification of N‐terminal α‐amino group of β globin chain with glucose via Amadori rearrangement. Cation exchange chromatography exploits the difference in surface charges between GHb and native hemoglobin (HbA0) for their separation and quantification. However, glucose condensation is specific to primary amino groups. Therefore, structural characterization of GHb synthesized in vivo is essential as multiple glycation may interfere with GHb assessment. The stoichiometric composition of different glycated hemoglobin from a 19% GHb sample was deduced using native mass spectrometry. We observed a comparable population of α and β glycated tetramers for mono‐glycated HbA0. Surprisingly, doubly and triply glycated HbA0 also showed mono‐glycated α and β globins. Thus, we propose that glycation of hemoglobin (HbA) occurs symmetrically across α and β globins with preference to unmodified globin first. Correlation between conventional and mass spectrometry‐based quantification of GHb showed a reliable estimation of the glycemic index of individuals carrying HbA0. Mutant HbAs have different retention time than HbA0 due to the differences in their surface charge. Thus, their glycated analog may elute at different retention time compared to GHb. Consequently, our method would be ideal for assessing the glycemic index of an individual carrying mutant HbA.

17 February 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
CFCj San Felipe
Cj San Felipe
JBJyoti Batra
Jyoti Batra
MMMonita Muralidharan
Monita Muralidharan
SMShivali Malpotra
Shivali Malpotra
DADurga Anand
Durga Anand
JFJames S. Fraser
James S. Fraser
Open Reading Frame 9b (Orf9b), an accessory protein of SARS-CoV and -2, is involved in innate immune suppression through its binding to the mitochondrial receptor Translocase of Outer Membrane 70 (Tom70). Previous structural studies of Orf9b in isolation revealed a β-sheet-rich homodimer, however, structures of Orf9b in complex with Tom70 revealed a monomeric helical fold. Here, we developed a biophysical model that quantifies how Orf9b switches between these conformations and binds to Tom70, a requirement for suppressing the type 1 interferon response. We used this model to characterize the effect of lipid binding and mutations in variants of concern to the Orf9b:Tom70 equilibrium. We found that the binding of a lipid to the Orf9b homodimer biases the Orf9b monomer:dimer equilibrium towards the dimer by reducing the dimer dissociation rate ∼100-fold. We also found that mutations in variants of concern can alter different microscopic rate constants without significantly affecting binding to Tom70. Together our results highlight how perturbations to different steps in these coupled equilibria can affect the apparent affinity of Orf9b to Tom70, with potential downstream implications for interferon signaling in coronavirus infection.

12 August 2025 in eLife preprints
Verified
Preprint
Open access
CFCj San Felipe
Cj San Felipe
JBJyoti Batra
Jyoti Batra
MMMonita Muralidharan
Monita Muralidharan
SMShivali Malpotra
Shivali Malpotra
DADurga Anand
Durga Anand
JFJames S Fraser
James S Fraser
Open Reading Frame 9b (Orf9b), an accessory protein of SARS-CoV and -2, is involved in innate immune suppression through its binding to the mitochondrial receptor Translocase of Outer Membrane 70 (Tom70). Previous structural studies of Orf9b in isolation revealed a β-sheet-rich homodimer, however, structures of Orf9b in complex with Tom70 revealed a monomeric helical fold. Here, we developed a biophysical model that quantifies how Orf9b switches between these conformations and binds to Tom70, a requirement for suppressing the type 1 interferon response. We used this model to characterize the effect of lipid binding and mutations in variants of concern to the Orf9b:Tom70 equilibrium. We found that the binding of a lipid to the Orf9b homodimer biases the Orf9b monomer:dimer equilibrium towards the dimer by reducing the dimer dissociation rate ∼100-fold. We also found that mutations in variants of concern can alter different microscopic rate constants without significantly affecting binding to Tom70. Together our results highlight how perturbations to different steps in these coupled equilibria can affect the apparent affinity of Orf9b to Tom70, with potential downstream implications for interferon signaling in coronavirus infection.